A study of placebo treatment of acute symptomatic urinary tract infection in non-pregnant women showed that about 80%4 obtained sterile urine spontaneously within 5 months. About one-half of these had recurrent infection within a year.
Introduction
The reasons why some, but not all, apparently healthy women acquire urinary tract infection are still not known, and causal treatment is not possible. In orderto relieve discomfort, prevent septicaemia and, if possible, progressive renal damage in bacteriuric patients, efforts are directed towards sterilization of the urinary tract. Innumerable studies have shown that this can be done by appropriate use of antimicrobial therapy. But it is difficult to evaluate whether treatment significantly alters the course of urinary tract infection in women.
In the present study a follow-up was made on non-pregnant women with uncomplicated urinary tract infection, in order to get an impression of the outcome of short-term therapy and the possibilities of reducing periods with bacteriuria.
Patients and methods
During the period October 1966 to July 1968, general practitioners in the Roskilde region were requested to refer to the medical out-patient clinic all non-pregnant women between 16 and 65 years old with symptoms of urinary tract infection. Four hundred and seventy-two women were referred. Among these, 219 women with bacteriuria and serum-creatinine values below 1-4 mg/100 ml were found. Urography performed on 210 of the bacteriuric patients revealed renal calculi in five cases, which were excluded from the study. No case of severe hydronephrosis or hydroureter was found.
The minimum criterion of bacteriuria was: more than 105 bacteria/ml in at least two consecutive midstream specimens, the same organism being cultured from both. In 499 out of 558 instances of bacteriuria detected during the study the diagnosis was established by culture of more than 106 organisms/ml in at least one of the specimens, by more than 105/ml in three or more consecutive specimens, or by culture from urine aspirated by suprapubic bladder puncture. Quantitative culture of urine was made on lactose-agar and on blood-agar plates with a calibrated loop, streaking the inoculum over the whole plate with a sterile glass rod. The bacteria isolated were identified by the Department of Diagnostic Bacteriology, State Serum Institute, Copenhagen. All strains of Escherichia coli were typed for 0-and H-antigens by the International Escherichia Centre, State Serum Institute.
Maximum urinary concentrating ability was measured by determination of urine osmolality 14-18 hr after the administration of 5 IU of vasopressin tannate in oil ('Pitressin' tannate; Parke, Davis) (DeWardener, 1956; Mabeck, 1970) . Coliantibody titre in serum was determined using the indirect haemagglutination technique (Mabeck, 1970) .
In a double-blind trial, one-third of the patients were allocated to each of three therapeutic groups as shown in Table 1 . Seven patients who were staff members, and seven who had severe acute pyelonephritis were excluded from the placebo trial and received treatment as scheduled for recurrent infections (see below). Nine did not complete treatment and thirty-two (including three excluded from the placebo trial) did not complete a 1-year follow-up (Table 2) . Tablets for the first 2 weeks' treatment were distributed in code-numbered bottles; antimicrobial agents were chosen in accordance with the result of the susceptibility test, but one-third of the bottles contained placebo tablets (Table 1 ). The dosages were: sulphamethizol 2 g, ampicillin 1 g, oxytetracycline 1 g, or chloramphenicol 1 g daily, divided in four doses.
In a further double-blind trial all recurrences were allocated to treatment schemes I and II (Table 1) .
After initiation of treatment, urine cultures were made after I, 2, 4 and 8 weeks, and thereafter every third month. During the follow-up all patients were instructed to report immediately upon symptoms of urinary tract infection. It was intended to follow all patients for at least 2 years, though not beyond March 1970.
Definitions
Failure is defined as persistence of bacteriuria during treatment, and recurrence as reappearance of bacteriuria after a period with less than 104 organisms/ml mid-stream urine. Recrudescence is recurrence with bacteria of the same species and serotype as found before treatment, while reinfection is defined as change in the urinary flora or recurrence with a different organism.
Results

Placebo treatment
Sixty-three patients received placebo (group III) and fifty-three of these were followed for more than 12 months (Table 2) . During the first 12 months eight of these patients, because of persistent or recurrent subjective symptoms received active treatment before the urine became sterile (Fig. 1) . Of the remaining forty-five patients, two had persistent bacteriuria, while forty-three attained sterile urine without further treatment. In thirty-two patients the urine became sterile within a month and in all fortythree cases within 5 months.
Recrudescence occurred in ten cases and ten patients were reinfected within a year (Fig. 1) .
Relief of clinical symptoms does not indicate success of treatment. In twenty-one out of twentythree patients with bacteriuria for more than 4 weeks the symptoms disappeared before the infection was eliminated.
Comparison of 2 and 4 weeks' treatment Two hundred cases of urinary tract infection were followed for 5 months or more after 2 weeks' antimicrobial treatment (group II). Two hundred and six cases, after 2 weeks' antimicrobial treatment, received chloramphenicol for a further 2-week period (group I). In both groups the frequency ofreinfection was 34°/ (Fig. 2) , while failure or recrudescence within 5 months occurred in twenty-four cases in group I and in thirty-nine cases in group II (P -0 05). There are several possible explanations for this difference, but it seems too small to be of clinical importance.
Course after treatment One hundred and forty-one out of 143 patients treated with sulphonamide or an antibiotic, achieved sterile urine during treatment and ninety-eight of these were followed for more than 23 months. During this follow-up recrudescence was detected in 71 sixteen cases and in eight of these it occurred within 2 months (Fig. 3) Recurrence rate for a given length of time (t2-t,)
can be calculated in relation to patients at risk at t1, i.e. the number of patients with sterile urine at the start of follow-up.
(No. of recurrences during t2-tl) x 100 (Patients at risk at t1) (t2-tJ)
The recurrence rate was calculated for each of the first 2 months and for every 3-month observation period thereafter. Figure 4 shows that the recurrence rate was high during the first 2 months and thereafter fairly constant. The risk of further recurrences diminished with the length of time elapsing between the first and second infection. Sixty-nine actively treated patients had recurrent infection and were followed for at least 5 months after treatment of the second infection (Fig. 5) . Out of twenty-nine patients who had their first recurrence within 5 months after the initial treatment, only 48%Y maintained sterile urine for 5 months after the second treatment. In contrast, out of forty patients who had their first recurrence more than 5 months after the initial treatment, 80%o maintained sterile urine for 5 months or more after the second treatment (P <0 02).
The likelihood of recurrent infection within 5 months after treatment increased with the number of recurrences. After each recurrence the proportion of patients who maintained sterile urine for 5 months or more diminished by about 22%/ (Fig. 6 ). The higher recurrence rate was mainly due to an increasing number of recurrences within the first 2 months after treatment (Fig. 7) .
With increasing number of recurrences the relation between failure, recrudescence and reinfection remained unchanged (Table 3) , and the frequency of therapeutic failures rose only from about 1% to 8 6%Y. These findings suggest that in younger women with uncomplicated urinary tract infection the therapeutic problem lies not so much in eliminating bacteriuria as in detecting recurrence.
This implies the necessity of frequent urine culture in patients with a high recurrence rate. In the present study thirty-seven patients had four or more infections during the follow-up. They were followed for from 16 to 41 months (average 305 months) and attended the clinic an average of 17-4 times a year. In this group, 244 recurrences were detected, i.e. 2 6/ patient-year, while the remaining patients had only 032 recurrences/year. Out of these thirty-seven patients, thirteen were primarily placebo-treated and only five of these cleared up spontaneously. Patients with a high recurrence rate constituted the majority of those who had recurrent infection within 5 months after the initial treatment. Out of the twenty-four actively treated, twenty (83%/) had recurrent infection within 5 months. Of the remaining patients only 14°/ had a recurrence within 5 months (P <0 001).
In most of these thirty-seven patients the recurrence rate remained unchanged during the observation period, but some cases showed a remarkable reduction in the proneness to recurrent infection (Fig. 8) . Whether this was a result of therapy or inherent in the natural course of the disease is not known.
The probability of reinfection increased with age (P<005), and a high recurrence rate was more frequent among patients with raised coli antibody titre (P <005) or radiological signs of chronic pyelonephritis (P<0-01) (Table 4) . Otherwise no significant correlation was found between clinical parameters and recurrence rate.
Discussion
The association between urinary tract infection and acute pyelonephritis is well established. A major problem is to what extent uncomplicated urinary tract infection in younger women entails a risk of developing chronic pyelonephritis and renal failure.
The possibility that urinary infection sets up a chain reaction that leads to progressive pyelonephritis without subsequent evidence of infection (Angell, Relman & Robbins, 1968; Aoki et al., 1969) cannot be excluded. However, studies of children (Smellie & Normand, 1968) , paraplegics (Saito, 1964) , and pregnant women with bacteriuria (Kass, 1970) support the view that chronic and recurrent infection increases the risk of progressive renal damage.
Until more is known about the ultimate prognosis the aim of treatment must be to maintain sterile urine for as long as possible. This implies the necessity of early detection of recurrences. It is, therefore, of practical importance to know for how long after eradication of infection the patients must be followed in order to reveal recurrent urinary infection.
As in other studies it was found that by appropriate treatment of uncomplicated urinary tract infection sterile urine is obtained in nearly all cases. In evaluation of the immediate response to treatment two important facts should be noted. First, relief of symptoms is no indication that therapy has been effective. Nearly all placebo-treated patients in this study showed 'clinical improvement' despite persistence of bacteriuria. Second, that 'sterile urine' means that the number of bacteria/ml does not exceed the number of organisms with which midstream specimens are usually contaminated. This does not exclude the possibility of bacteriuria, because, during therapy, the bacterial count may be reduced to a few hundred or thousand.
Recrudescence occurred in about 15%. of the patients. In some cases this is probably due to failure to eradicate the organisms from the urinary tract. But if the bowel flora remains unchanged it is possible that a large proportion of reinfection within the first months after treatment are caused by the same organism that was responsible for the initial infection. Therefore, recrudescence represent the maximum number of cases in which the urinary tract Placebo-treated patients and patients followed for less than 1 year are excluded. * P < 0-05.
t P < 0-01.
has not been sterilized, but does not rule out the possibility of reinfection. Uncomplicated urinary tract infection in women shows a tendency towards spontaneous remission. Kass, Savage & Santamarina (1965) found, on reexamination of women with asymptomatic bacteriuria detected in population surveys, that 'each year, in about one-fourth of the adult female population the infection clears spontaneously'. Asscher et al. (1969) , in a 1-year follow-up of forty-five women with asymptomatic bacteriuria, who had been given a placebo, found that 36°/ had sterile urine. Similar results have been reported by Freedman, Seki & Phair (1965) . The remission rates found in these studies are probably too low because some patients, after their infection had cleared up spontaneously, may have become reinfected within the observation period.
In the present study about 80°/ of placebotreated patients attained sterile urine spontaneously. But nearly one-half of them had recurrent infection within the first year. Recurrences were treated and the proportion of patients with sterile urine after 1 year is, therefore, not comparable with previous studies. However, 43%/ maintained sterile urine after spontaneous remission, and the possibility that acute symptomatic infections clear up more readily than asymptomatic infections cannot be ruled out. The difference between the course of acute symptomatic infections and asymptomatic infections revealed by screening programmes might be due to an overrepresentation of chronic and long-standing bacteriuria in screening studies.
In comparison with placebo treatment, antimicrobials produced a high immediate cure rate but only 60%O maintained sterile urine for 1 year. In other studies even smaller differences between treated and untreated have been found (Asscher et al., 1969; Freedman et al., 1965) .
Most recurrences in uncomplicated urinary tract infections are due to reinfection. In the present study, 71 %Y of recurrences were reinfections. Similar findings have been reported by Kunin (1970) and McGeachie (1966) , while in complicated urinary group.bmj.com on June 20, 2017 -Published by http://pmj.bmj.com/ Downloaded from tract infection and in advanced chronic pyelonephritis the majority of recurrences are due to recrudescence (Turck, Anderson & Petersdorf, 1966; McCabe & Jackson, 1965) .
Recrudescence due to insufficient sterilization of the urinary tract will result in recurrence shortly after discontinuation of therapy. This contributes to the high recurrence rate during the first 2 months after treatment. Thereafter, in the present study, the recurrence rate became constant for the next 20 months. This seems to be in contrast with the course in complicated urinary tract infection or advanced chronic pyelonephritis. In such patients McCabe & Jackson (1965) found that the reinfection rate decreased from 3-2y//month during the first year to 0-5%. during the second, and 0 2% during the third year after elimination of bacteriuria. In their study reinfection accounted for one-third of recurrences only.
Patients with many recurrences probably constitute a group with an increased risk of developing renal failure and they should receive special attention. In the present study one-sixth of the patients accounted for 70°/ of all recurrences detected. The frequency of spontaneous remission was lower in this group, while the proportion of recurrences due to failures or recrudescence did not increase with the number of infections.
The majority of patients with many recurrences had their first recurrence within 5 months after the initial treatment. As no single symptom or sign can predict which patient will have recurrent infection, it is necessary to follow patients with uncomplicated urinary tract infection for at least half a year after treatment in order to identify those who have recrudescence or a high recurrence rate.
Follow-up means culture of urine at regular intervals, because 39°/ of recurrences were asymptomatic and many cases had only transient clinical symptoms. 
